Drug Trial Radar · NCT00435461
Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine
Last checked: Nov 19, 2026Latest source record: Mar 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Actual
Start
Dec 20, 2006
Primary completion
Feb 1, 2007
Study completion Feb 28, 2007
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the nighttime symptom relief of fluticasone furoate nasal spray and oral fexofenadine
Conditions
- Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate and fexofenadineDrug
Fluticasone furoate and fexofenadine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Symptoms Score (NSS)Time frame: Baseline (Day 1) and up to 2 Weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Kerrville, Texas
GSK Investigational Site
New Braunfels, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.